John W. Greiner, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 8B04
- Bethesda, MD 20892-1750
The Animal Protocols Facility is responsible for the assessment and oversight of the Center for Immuno-Oncology (CIO) Animal Care & Use Program components, compliance required by the NCI-ACUC guidelines, AALAC accreditation and facilities, including the review and approval of animal research protocols, evaluation of animal use and housing areas, monitoring and evaluation of animal use practices, review and approval of policies and standards for animal care and use, and investigation of animal welfare concerns. Additionally, the group is responsible for the management of several mouse colonies, which include transgenic mice and mice harboring genetic mutations, that results in the development of spontaneous tumors to be made available to many investigators within the CIO for preclinical studies.
Areas of Expertise
1) immunology, 2) immunotherapy
Development of More Valid Animal Models for the Analysis of New Vaccine Strategies
Emphasis is currently being placed on the development of new animal models that are more appropriate for the analysis of new vaccines and vaccine strategies than the conventional prevention or treatment models, where vaccines are given a few days before or after transplant of a rapidly growing tumor. A particular interest has developed in mouse bladder tumor models that utilize intravital imaging of orthotopically instilled bladder tumors. A CEA-transgenic (Tg) mouse, where CEA is a 'self antigen' and is expressed in levels and tissues similar to those in humans, is being employed along with experimental liver metastases expressing CEA positive colon carcinoma cells. Moreover, CEA Tg mice have been crossed with min+ Tg mice; min+ Tg mice contain a mutant APC gene and develop numerous colonic polyps that ultimately cause their death. We have now developed a min+ x CEA+ double transgenic model in which spontaneous colon tumors arise that express CEA.
Studies are planned to evaluate new vaccines and vaccine strategies in this and other Tg models. Studies are also ongoing and planned to develop and evaluate other murine models that develop spontaneous tumors, which contain a 'self antigen' as a potential vaccine target.
Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein
Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice
John W. Greiner, Ph.D.
Dr. Greiner, Staff Scientist, Facilities Manager, in the Center for Immuno-Oncology's Translational Research area, is responsible, with Robin Riley, for the Animal Protocols Facility. He received his Ph.D. in Physiology and Biophysics from West Virginia University, Morgantown, WV. Dr. Greiner's research interests are in immunology and immunotherapy.